Developer docs
API playgroundTry for free, no card

Search company profiles

Sciwind Biosciences

Full company profile

uuid0000ztf

Namestring
Sciwind Biosciences
Legal namestring
杭州先为达生物科技股份有限公司
Websiteurl
sciwind.com.cn
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Sciwind Biosciences (杭州先为达生物科技股份有限公司) is a commercial-stage Chinese biopharmaceutical company founded in 2017 in Hangzhou, focused on developing innovative therapies for metabolic diseases, with particular emphasis on weight management. Its lead asset, ecnoglutide injection (brand names 先维盈®/先颐达®), became the world's first approved cAMP-biased GLP-1 receptor agonist after receiving NMPA approval in January 2026 for type 2 diabetes and March 2026 for chronic weight management, followed by commercial launch in May 2026. Phase 3 data demonstrated 15.4% mean body weight reduction at 48 weeks, 2.43% HbA1c reduction, and only 0.6% discontinuation due to gastrointestinal adverse events, with a head-to-head Phase 2 trial showing 35% greater weight loss than semaglutide. The underlying technology is the SciwindCore™ platform, comprising three proprietary systems: BiasVantage™ for biased agonist discovery (selective cAMP pathway activation with minimized β-arrestin recruitment), OralVantage™ for oral peptide delivery, and HaleVantage™ for half-life extension via fatty acid modification and antibody-peptide conjugation. The pipeline includes 14+ assets spanning oral ecnoglutide (XW004), oral small molecule GLP-1 (XW014), amylin receptor agonists (XW015/XW016), a Sanofi-licensed GIP analog (XW017), a monthly injection (XW019), and a muscle-preserving peptide (XW020), supported by 110+ patents/patent applications and a 120+ person R&D team.

Sciwind operates a hybrid licensing-plus-supply business model. The company serves as the Marketing Authorization Holder (MAH) responsible for R&D, registration, manufacturing, and supply, while commercialization is executed by partners: Pfizer for Mainland China (up to $495M deal value), Verdiva Bio for global rights excluding Greater China and Korea (~$70M upfront plus up to $2.4B in milestones plus tiered royalties), and HK inno.N for South Korea (up to $56M plus high double-digit royalties). Revenue is generated through licensing upfronts, regulatory and commercial milestone payments, product supply to commercial partners, and eventually royalties on partner-led sales. The customer base is essentially three multinational pharmaceutical partners, which provides distribution reach but creates concentration risk. Operations span China (Hangzhou HQ, Beijing R&D, Shanghai branch), the United States (San Ramon, CA subsidiary established 2020 for overseas clinical and BD), and Australia (Collingwood subsidiary established 2019 for international clinical development), enabling global clinical execution while retaining manufacturing control in China.

Short descriptiontext

Sciwind Biosciences is a Hangzhou-based commercial-stage biopharmaceutical company developing cAMP-biased GLP-1 receptor agonist therapies for metabolic diseases, with its approved lead product ecnoglutide serving obesity and type 2 diabetes patients via global licensing partnerships with Pfizer, Verdiva Bio, and HK inno.N.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHangzhou, China
HQ citystring
Hangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metabolic disease therapeutics, GLP-1 receptor agonists, weight management drugs, peptide drug development, type 2 diabetes treatment
Industry2 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Metabolic Disease Biopharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and milestone payments
TypeLicensing Royalties
Description

Sciwind receives upfront payments, regulatory milestones, and sales milestones from commercialization partners. For the Pfizer China deal, Sciwind is eligible to receive up to $495 million in upfront, regulatory and sales milestone payments. For the Verdiva Bio global deal, Sciwind receives approximately $70 million in signing payments and is eligible for up to $2.4 billion in development, registration and commercial milestones plus tiered sales royalties.

prnewswire.com
2Product sales
TypeHardware Sales
Description

As the Marketing Authorization Holder, Sciwind manufactures and supplies ecnoglutide injection to its commercial partners (Pfizer in China), generating revenue from product supply.

sciwind.com.cn
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1先维盈®
Description

Brand name for ecnoglutide injection for chronic weight management in adults with overweight or obesity.

sciwind.com.cn
+5 more records
Core offering1 text field

Sciwind Biosciences is a commercial-stage biopharmaceutical company that develops and manufactures innovative peptide and small molecule therapies for metabolic diseases, primarily obesity and type 2 diabetes. Its core marketed product is Ecnoglutide Injection (XW003), the world's first approved cAMP-biased GLP-1 receptor agonist, sold in China under the brand names Xianyida (先颐达) for type 2 diabetes and Xianweiying (先维盈) for chronic weight management. The company also operates a pipeline of injectable, oral peptide, oral small molecule, amylin, GIP, and complementary mechanism candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 15.4% average body weight reduction at 48 weeks (15.1% placebo-adjusted) in Phase 3 SLIMMER trial with 92.8% of patients achieving ≥5% weight loss
+5 more records
Product overview1 text field

Sciwind Biosciences is a commercial-stage biopharmaceutical company focused on developing innovative therapies for metabolic diseases, particularly weight management. The company's core product is Ecnoglutide Injection (先维盈®/先颐达®), the world's first approved cAMP-biased GLP-1 receptor agonist, which received NMPA approval in January 2026 for type 2 diabetes and March 2026 for weight management. The product portfolio includes injectable, oral peptide, and oral small molecule GLP-1 formulations (XW004, XW014), amylin-based therapies (XW015, XW016), a GIP analog (XW017), next-generation monthly injection (XW019), muscle-preserving weight loss therapy (XW020), and an interferon-based antiviral (XW001). The company operates three technology platforms: BiasVantage™ (biased agonist discovery), OralVantage™ (oral peptide delivery), and HaleVantage™ (half-life extension).

Product and service9 records
1Ecnoglutide Injection (先维盈/先颐达, Ecnoglutide, XW003)
CategoryGLP-1 receptor agonist (injection)
Description

World's first approved cAMP-biased GLP-1 receptor agonist, a once-weekly subcutaneous injection for adult type 2 diabetes blood glucose control and chronic weight management in adults with overweight or obesity. Demonstrated 15.4% mean body weight reduction at 48 weeks and 2.43% HbA1c reduction in Phase 3 trials.

2XW004 (Oral Ecnoglutide)
CategoryOral GLP-1 peptide therapy
Description

Once-weekly oral peptide formulation of ecnoglutide with 3-5x higher oral bioavailability than existing oral GLP-1 therapies; in clinical development for overweight/obesity.

3XW014 (Oral Small Molecule GLP-1 RA)
CategoryOral small molecule GLP-1 therapy
Description

Oral small molecule cAMP-biased GLP-1 receptor agonist in Phase I clinical trials offering manufacturing scalability, cost-effectiveness advantages, and potential for fixed-dose combination with other oral drugs.

4XW015 (Amylin Injection)
CategoryAmylin receptor agonist (injection)
Description

Long-acting injectable amylin receptor agonist in preclinical/IND stage designed to enhance satiety and support sustained weight loss with potentially milder gastrointestinal side effects compared to GLP-1 monotherapy.

5XW016 (Amylin Oral)
CategoryOral amylin peptide therapy
Description

Oral amylin peptide analog (among the world's first) leveraging proprietary OralVantage delivery technology and optimized fatty acid modification for high oral bioavailability and combination formulation feasibility.

6XW017 (GIP Analog)
CategoryGIP receptor agonist
Description

Long-acting GIP (glucose-dependent insulinotropic polypeptide) receptor agonist with optimized biological activity and in vivo stability, intended for combination therapy with ecnoglutide for synergistic metabolic effects.

7XW019 (Monthly Injection)
CategoryLong-acting injectable peptide therapy
Description

Monthly-administration biologic injection in early research stage targeting multiple complementary mechanisms to enhance metabolic balance and sustained weight reduction with improved patient convenience.

8XW020 (Muscle-Preserving Injection)
CategoryLong-acting injectable peptide therapy
Description

Long-acting injectable peptide with dual weight loss and muscle-preservation effects, addressing the muscle-loss limitation of existing weight loss therapies.

9XW001 (IL-29 / Interferon Lambda)
CategoryAntiviral biologic (interferon)
Description

Human interleukin-29 (IL-29) analog (interferon lambda, IFNλ) designed for respiratory virus infection treatment including RSV, influenza, and other respiratory infections with high unmet clinical needs.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-24
Description

Strategic commercialization collaboration granting Pfizer exclusive commercialization rights for ecnoglutide injection in Mainland China. Sciwind remains Marketing Authorization Holder responsible for R&D, registration, manufacturing and supply. Deal valued up to $495 million including upfront, regulatory and sales milestones.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-01-10
Description

Global development and commercialization licensing agreement for metabolic disease product portfolio including oral ecnoglutide (XW004) and amylin receptor agonists, excluding Greater China and Korea. Deal includes near $70 million signing payment and up to $2.4 billion in potential development, registration and commercial milestones plus tiered sales royalties.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-07
Description

Licensing agreement granting HK inno.N exclusive rights to develop and commercialize ecnoglutide injection in South Korea for type 2 diabetes, obesity and MASH. Sciwind eligible for up to $56 million in development, registration and commercial milestones plus high double-digit sales royalties.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-27
Description

Collaboration to develop siRNA-based innovative therapies for liver and metabolic diseases. Partnership combines Sciwind's disease biology and clinical development expertise with SynerK's proprietary siRNA delivery technology platform.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-11-30
Description

Global exclusive licensing agreement for Sanofi's long-acting GIP receptor agonist program for co-development with Sciwind's GLP-1 candidates. GIP receptor agonist has potential to further enhance efficacy and improve safety profile of GLP-1 combination therapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global GLP-1 leader with semaglutide (Ozempic/Wegovy) for T2D and obesity. Directly comparable as the incumbent benchmark Sciwind's ecnoglutide has shown superiority over in head-to-head trials; competition for global market share defines Sciwind's commercial ceiling.

2Hansoh Pharmaceutical
TypeBroad incumbent
Description

Major Chinese innovative pharma with a metabolic disease pipeline including GLP-1 candidates. Comparable as a large Chinese pharma with established commercialization infrastructure that Sciwind may compete against for hospital access and physician relationships.

TypeRegional player
Description

Chinese insulin and peptide manufacturer developing GLP-1 biosimilars and novel peptides. Relevant peer in the Chinese peptide manufacturing and commercialization ecosystem; competes indirectly through similar patient channels and pricing dynamics.

TypeEmerging player
Description

Chinese biotech developing GIP/GLP-1 dual agonists (PEG-100) and long-acting peptide formulations for metabolic disease. Comparable Chinese-headquartered emerging player in GLP-1-adjacent space targeting similar patient populations.

TypeEmerging player
Description

Clinical-stage biotech developing oral small molecule GLP-1 receptor agonists (GSBR-1290). Directly comparable as an emerging player targeting the same oral GLP-1 opportunity that Sciwind addresses with XW014, with both competing for physician and patient mindshare in obesity/T2D.

TypeDirect peer
Description

Chinese biopharma with mazdutide (GLP-1/glucagon dual agonist) partnered with Eli Lilly for China commercialization. Closest Chinese-headquartered direct peer in the GLP-1 obesity/diabetes space, competing for similar prescribers, patients, and NMPA positioning.

TypeEmerging player
Description

US-listed biotech developing oral GLP-1 (TERN-601) and NASH therapies. Founded by Sciwind's Chief Strategy Officer Dr. Weidong Zhong; comparable in therapeutic area (metabolic disease) and stage (early clinical to mid-stage), and represents an alternative investment in the same space.

TypeOthers
Description

Newly established biotech that licensed Sciwind's oral ecnoglutide and amylin programs globally. While a partner rather than competitor, Verdiva's success in commercializing these assets directly affects Sciwind's milestone realization and royalty economics.

TypeEmerging player
Description

Pre-acquisition developer of CT-388 (GLP-1/GIP dual agonist) acquired by Roche. Representative comparable for the GLP-1/GIP dual agonist competitive set relevant to Sciwind's XW017 program and combination strategy.

TypeBroad incumbent
Description

Developer of tirzepatide (Mounjaro/Zepbound) and advancing oral orforglipron and retatrutide. The other dominant GLP-1 incumbent; Sciwind's CSO and CEO both held prior roles at Lilly, and the company's clinical positioning is defined relative to Lilly's portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sciwind Biosciences

Metabolic Disease Biopharmaceuticalssciwind.com.cn

Sciwind Biosciences is a Hangzhou-based commercial-stage biopharmaceutical company developing cAMP-biased GLP-1 receptor agonist therapies for metabolic diseases, with its approved lead product ecnoglutide serving obesity and type 2 diabetes patients via global licensing partnerships with Pfizer, Verdiva Bio, and HK inno.N.

What Sciwind Biosciences does

Sciwind Biosciences (杭州先为达生物科技股份有限公司) is a commercial-stage Chinese biopharmaceutical company founded in 2017 in Hangzhou, focused on developing innovative therapies for metabolic diseases, with particular emphasis on weight management. Its lead asset, ecnoglutide injection (brand names 先维盈®/先颐达®), became the world's first approved cAMP-biased GLP-1 receptor agonist after receiving NMPA approval in January 2026 for type 2 diabetes and March 2026 for chronic weight management, followed by commercial launch in May 2026. Phase 3 data demonstrated 15.4% mean body weight reduction at 48 weeks, 2.43% HbA1c reduction, and only 0.6% discontinuation due to gastrointestinal adverse events, with a head-to-head Phase 2 trial showing 35% greater weight loss than semaglutide. The underlying technology is the SciwindCore™ platform, comprising three proprietary systems: BiasVantage™ for biased agonist discovery (selective cAMP pathway activation with minimized β-arrestin recruitment), OralVantage™ for oral peptide delivery, and HaleVantage™ for half-life extension via fatty acid modification and antibody-peptide conjugation. The pipeline includes 14+ assets spanning oral ecnoglutide (XW004), oral small molecule GLP-1 (XW014), amylin receptor agonists (XW015/XW016), a Sanofi-licensed GIP analog (XW017), a monthly injection (XW019), and a muscle-preserving peptide (XW020), supported by 110+ patents/patent applications and a 120+ person R&D team.

Sciwind operates a hybrid licensing-plus-supply business model. The company serves as the Marketing Authorization Holder (MAH) responsible for R&D, registration, manufacturing, and supply, while commercialization is executed by partners: Pfizer for Mainland China (up to $495M deal value), Verdiva Bio for global rights excluding Greater China and Korea (~$70M upfront plus up to $2.4B in milestones plus tiered royalties), and HK inno.N for South Korea (up to $56M plus high double-digit royalties). Revenue is generated through licensing upfronts, regulatory and commercial milestone payments, product supply to commercial partners, and eventually royalties on partner-led sales. The customer base is essentially three multinational pharmaceutical partners, which provides distribution reach but creates concentration risk. Operations span China (Hangzhou HQ, Beijing R&D, Shanghai branch), the United States (San Ramon, CA subsidiary established 2020 for overseas clinical and BD), and Australia (Collingwood subsidiary established 2019 for international clinical development), enabling global clinical execution while retaining manufacturing control in China.

Sciwind Biosciences firmographics

Firmographics
Name
Sciwind Biosciences
Legal name
杭州先为达生物科技股份有限公司
Website
https://sciwind.com.cn
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Sciwind Biosciences is a Hangzhou-based commercial-stage biopharmaceutical company developing cAMP-biased GLP-1 receptor agonist therapies for metabolic diseases, with its approved lead product ecnoglutide serving obesity and type 2 diabetes patients via global licensing partnerships with Pfizer, Verdiva Bio, and HK inno.N.
Ownership category
akta.pro rank

Sciwind Biosciences industry classification

Industry
Product category
Metabolic Disease Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Metabolic disease therapeutics
  • GLP-1 receptor agonists
  • Weight management drugs
  • Peptide drug development
  • Type 2 diabetes treatment

Where Sciwind Biosciences is headquartered

Location

Headquarters

HQ city
Hangzhou
HQ country
China
HQ region
Asia

Offices5 records

Markets served

Sciwind Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and milestone payments: Sciwind receives upfront payments, regulatory milestones, and sales milestones from commercialization partners. For the Pfizer China deal, Sciwind is eligible to receive up to $495 million in upfront, regulatory and sales milestone payments. For the Verdiva Bio global deal, Sciwind receives approximately $70 million in signing payments and is eligible for up to $2.4 billion in development, registration and commercial milestones plus tiered sales royalties.
  2. Product sales: As the Marketing Authorization Holder, Sciwind manufactures and supplies ecnoglutide injection to its commercial partners (Pfizer in China), generating revenue from product supply.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Sciwind Biosciences product offering

Product offering

Core offering

Sciwind Biosciences is a commercial-stage biopharmaceutical company that develops and manufactures innovative peptide and small molecule therapies for metabolic diseases, primarily obesity and type 2 diabetes. Its core marketed product is Ecnoglutide Injection (XW003), the world's first approved cAMP-biased GLP-1 receptor agonist, sold in China under the brand names Xianyida (先颐达) for type 2 diabetes and Xianweiying (先维盈) for chronic weight management. The company also operates a pipeline of injectable, oral peptide, oral small molecule, amylin, GIP, and complementary mechanism candidates.

Product overview

Sciwind Biosciences is a commercial-stage biopharmaceutical company focused on developing innovative therapies for metabolic diseases, particularly weight management. The company's core product is Ecnoglutide Injection (先维盈®/先颐达®), the world's first approved cAMP-biased GLP-1 receptor agonist, which received NMPA approval in January 2026 for type 2 diabetes and March 2026 for weight management. The product portfolio includes injectable, oral peptide, and oral small molecule GLP-1 formulations (XW004, XW014), amylin-based therapies (XW015, XW016), a GIP analog (XW017), next-generation monthly injection (XW019), muscle-preserving weight loss therapy (XW020), and an interferon-based antiviral (XW001). The company operates three technology platforms: BiasVantage™ (biased agonist discovery), OralVantage™ (oral peptide delivery), and HaleVantage™ (half-life extension).

Differentiator

Problem solved

Functional benefit

Brands

  • 先维盈®: Brand name for ecnoglutide injection for chronic weight management in adults with overweight or obesity.
  • 先颐达®
  • SciwindCore™
  • BiasVantage™
  • OralVantage™
  • HaleVantage™

Products and services

  • Ecnoglutide Injection (先维盈/先颐达, Ecnoglutide, XW003) World's first approved cAMP-biased GLP-1 receptor agonist, a once-weekly subcutaneous injection for adult type 2 diabetes blood glucose control and chronic weight management in adults with overweight or obesity. Demonstrated 15.4% mean body weight reduction at 48 weeks and 2.43% HbA1c reduction in Phase 3 trials.
  • XW004 (Oral Ecnoglutide) Once-weekly oral peptide formulation of ecnoglutide with 3-5x higher oral bioavailability than existing oral GLP-1 therapies; in clinical development for overweight/obesity.
  • XW014 (Oral Small Molecule GLP-1 RA) Oral small molecule cAMP-biased GLP-1 receptor agonist in Phase I clinical trials offering manufacturing scalability, cost-effectiveness advantages, and potential for fixed-dose combination with other oral drugs.
  • XW015 (Amylin Injection) Long-acting injectable amylin receptor agonist in preclinical/IND stage designed to enhance satiety and support sustained weight loss with potentially milder gastrointestinal side effects compared to GLP-1 monotherapy.
  • XW016 (Amylin Oral) Oral amylin peptide analog (among the world's first) leveraging proprietary OralVantage delivery technology and optimized fatty acid modification for high oral bioavailability and combination formulation feasibility.
  • XW017 (GIP Analog) Long-acting GIP (glucose-dependent insulinotropic polypeptide) receptor agonist with optimized biological activity and in vivo stability, intended for combination therapy with ecnoglutide for synergistic metabolic effects.
  • XW019 (Monthly Injection) Monthly-administration biologic injection in early research stage targeting multiple complementary mechanisms to enhance metabolic balance and sustained weight reduction with improved patient convenience.
  • XW020 (Muscle-Preserving Injection) Long-acting injectable peptide with dual weight loss and muscle-preservation effects, addressing the muscle-loss limitation of existing weight loss therapies.
  • XW001 (IL-29 / Interferon Lambda) Human interleukin-29 (IL-29) analog (interferon lambda, IFNλ) designed for respiratory virus infection treatment including RSV, influenza, and other respiratory infections with high unmet clinical needs.

Quantifiable outcome

  • 15.4% average body weight reduction at 48 weeks (15.1% placebo-adjusted) in Phase 3 SLIMMER trial with 92.8% of patients achieving ≥5% weight loss
  • +5 more outcomes

Companies that use Sciwind Biosciences

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Sciwind Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Sciwind Biosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, major and minor.

  • Pfizer ChinacoreChannel Partner/ Reseller/ Distributor · 24 February 2026Strategic commercialization collaboration granting Pfizer exclusive commercialization rights for ecnoglutide injection in Mainland China. Sciwind remains Marketing Authorization Holder responsible for R&D, registration, manufacturing and supply. Deal valued up to $495 million including upfront, regulatory and sales milestones.
  • Verdiva Bio LimitedcoreChannel Partner/ Reseller/ Distributor · 10 January 2025Global development and commercialization licensing agreement for metabolic disease product portfolio including oral ecnoglutide (XW004) and amylin receptor agonists, excluding Greater China and Korea. Deal includes near $70 million signing payment and up to $2.4 billion in potential development, registration and commercial milestones plus tiered sales royalties.
  • HK inno.N CorporationmajorChannel Partner/ Reseller/ Distributor · 7 May 2024Licensing agreement granting HK inno.N exclusive rights to develop and commercialize ecnoglutide injection in South Korea for type 2 diabetes, obesity and MASH. Sciwind eligible for up to $56 million in development, registration and commercial milestones plus high double-digit sales royalties.
  • 施能康 (SynerK)minorStrategic or Co-development Partner · 27 September 2022Collaboration to develop siRNA-based innovative therapies for liver and metabolic diseases. Partnership combines Sciwind's disease biology and clinical development expertise with SynerK's proprietary siRNA delivery technology platform.
  • SanofimajorStrategic or Co-development Partner · 30 November 2021Global exclusive licensing agreement for Sanofi's long-acting GIP receptor agonist program for co-development with Sciwind's GLP-1 candidates. GIP receptor agonist has potential to further enhance efficacy and improve safety profile of GLP-1 combination therapies.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Sciwind Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Novo Nordisk: Global GLP-1 leader with semaglutide (Ozempic/Wegovy) for T2D and obesity. Directly comparable as the incumbent benchmark Sciwind's ecnoglutide has shown superiority over in head-to-head trials; competition for global market share defines Sciwind's commercial ceiling.
  • Hansoh Pharmaceutical: Major Chinese innovative pharma with a metabolic disease pipeline including GLP-1 candidates. Comparable as a large Chinese pharma with established commercialization infrastructure that Sciwind may compete against for hospital access and physician relationships.
  • Eli Lilly: Developer of tirzepatide (Mounjaro/Zepbound) and advancing oral orforglipron and retatrutide. The other dominant GLP-1 incumbent; Sciwind's CSO and CEO both held prior roles at Lilly, and the company's clinical positioning is defined relative to Lilly's portfolio.

Regional players

  • Gan & Lee Pharmaceuticals: Chinese insulin and peptide manufacturer developing GLP-1 biosimilars and novel peptides. Relevant peer in the Chinese peptide manufacturing and commercialization ecosystem; competes indirectly through similar patient channels and pricing dynamics.

Emerging players

  • PegBio: Chinese biotech developing GIP/GLP-1 dual agonists (PEG-100) and long-acting peptide formulations for metabolic disease. Comparable Chinese-headquartered emerging player in GLP-1-adjacent space targeting similar patient populations.
  • Structure Therapeutics: Clinical-stage biotech developing oral small molecule GLP-1 receptor agonists (GSBR-1290). Directly comparable as an emerging player targeting the same oral GLP-1 opportunity that Sciwind addresses with XW014, with both competing for physician and patient mindshare in obesity/T2D.
  • Terns Pharmaceuticals: US-listed biotech developing oral GLP-1 (TERN-601) and NASH therapies. Founded by Sciwind's Chief Strategy Officer Dr. Weidong Zhong; comparable in therapeutic area (metabolic disease) and stage (early clinical to mid-stage), and represents an alternative investment in the same space.
  • Carmot Therapeutics: Pre-acquisition developer of CT-388 (GLP-1/GIP dual agonist) acquired by Roche. Representative comparable for the GLP-1/GIP dual agonist competitive set relevant to Sciwind's XW017 program and combination strategy.

Direct peers

  • Innovent Biologics: Chinese biopharma with mazdutide (GLP-1/glucagon dual agonist) partnered with Eli Lilly for China commercialization. Closest Chinese-headquartered direct peer in the GLP-1 obesity/diabetes space, competing for similar prescribers, patients, and NMPA positioning.

Others

  • Verdiva Bio: Newly established biotech that licensed Sciwind's oral ecnoglutide and amylin programs globally. While a partner rather than competitor, Verdiva's success in commercializing these assets directly affects Sciwind's milestone realization and royalty economics.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Sciwind Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sciwind Biosciences leadership team

Management profile

Number of profiles

Profiles5 records

Sciwind Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Sciwind Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sciwind Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sciwind Biosciences

What does Sciwind Biosciences do?

Sciwind Biosciences is a commercial-stage biopharmaceutical company that develops and manufactures innovative peptide and small molecule therapies for metabolic diseases, primarily obesity and type 2 diabetes. Its core marketed product is Ecnoglutide Injection (XW003), the world's first approved cAMP-biased GLP-1 receptor agonist, sold in China under the brand names Xianyida (先颐达) for type 2 diabetes and Xianweiying (先维盈) for chronic weight management. The company also operates a pipeline of injectable, oral peptide, oral small molecule, amylin, GIP, and complementary mechanism candidates.

Is Sciwind Biosciences a public or private company?

Sciwind Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sciwind Biosciences founded?

Sciwind Biosciences was founded in 2017. It employs 1 to 10 people.

Where is Sciwind Biosciences based?

Sciwind Biosciences is headquartered in Hangzhou, China, in the Asia region.

How does Sciwind Biosciences make money?

Two revenue lines are on record. Licensing and milestone payments are the primary driver. The others are product sales.

Who are Sciwind Biosciences's main competitors?

Broad incumbents on record are Novo Nordisk, Hansoh Pharmaceutical and Eli Lilly. Gan & Lee Pharmaceuticals is listed as a regional player. Emerging players are PegBio, Structure Therapeutics, Terns Pharmaceuticals and Carmot Therapeutics. Innovent Biologics is listed as a direct peer. Verdiva Bio is listed as an others.

Does Sciwind Biosciences have an API?

No public API is recorded for Sciwind Biosciences.

What industry is Sciwind Biosciences in?

Sciwind Biosciences's product category is Metabolic Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerRace to launch weight-loss pills heats up as smaller players advanceMultiple companies are racing to launch oral obesity drugs, with Kailera's drug showing up to 10.9% weight loss in a China trial. Novo Nordisk and Eli Lilly have approved oral GLP-1 pills, while others like Structure and AstraZeneca are advancing candidates. Wall Street is revising its $150 billion market forecast.Phirda减肥药能否救辉瑞?Pfizer's revenue fell from $1003 billion in 2022 to $626 billion in 2025, with its COVID products' sales dropping 88%. The company acquired Metsera for $10 billion and other assets to enter the obesity drug market, with its first potential FDA approval expected in 2028.MarketScreenerRace to launch weight-loss pill heats up as Novo wins UK approvalNovo Nordisk received UK approval for its oral weight-loss drug Wegovy, securing U.S. clearance in December ahead of Eli Lilly's orforglipron. The global market faces generic competition and price pressure, prompting Wall Street to rethink a $150 billion forecast. Multiple companies are racing to launch oral GLP-1 drugs.pharmaphorumADA: Lilly's weight-loss reveal, and wannabes display waresEli Lilly presented data on retatrutide at ADA, showing up to 28.3% weight loss at 80 weeks in the TRIUMPH-1 study, with 65.3% of patients reaching a BMI below 30. The drug also improved knee osteoarthritis pain and sleep apnoea, and reduced cardiometabolic markers. Other companies showcased weight-loss and diabetes candidates, including Pfizer, Novo Nordisk, and Sciwind.AijournHead-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than SemaglutideHangzhou Sciwind Biosciences announced late-breaking clinical trial data at the 2026 ADA Scientific Sessions showing that ecnoglutide, the world's first approved cAMP-biased GLP-1 receptor agonist, demonstrated 35% greater weight loss compared to semaglutide in a head-to-head study of 163 obese patients across 17 research centers in China. The study showed that 74% of ecnoglutide patients achieved ≥10% body weight loss versus 40% for semaglutide, with a favorable gastrointestinal safety profile. Pfizer, which holds exclusive commercialization rights for ecnoglutide in Mainland China, stated it is proud to support the introduction of this therapy.PR NewswireHead-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than SemaglutideSciwind Biosciences announced that its cAMP-biased GLP-1 receptor agonist ecnoglutide demonstrated a 35% greater reduction in body weight compared to semaglutide at Week 20 in the SLIMMER-UP-SWITCH head-to-head Phase 2 clinical trial, with mean weight reduction of 12.8% versus 9.5% (P<0.0001) among 163 patients with obesity across 17 research centers in China. The study, presented as a Late-Breaking abstract at the 2026 ADA Scientific Sessions, also showed nearly twice as many ecnoglutide-treated patients achieved ≥10% body weight loss (74% vs 40%) and a 20% greater reduction in waist circumference. Pfizer, the exclusive commercialization partner for injectable ecnoglutide in Mainland China, highlighted the findings as evidence supporting new-generation biased GLP-1 therapies.BioSpaceObesity’s explosive growth continues as Q1 deals exceed total 2025 valueBiopharma companies committed $22 billion in obesity and diabetes licensing deals in Q1 2026, already surpassing 2025's full-year total of $20.3 billion, according to J.P. Morgan's Q1 licensing and venture report. While upfront cash and equity investments reached $1.3 billion in the quarter, GLP-1 and GIP-focused deals slowed to just two contracts in Q1 compared to eight for all of 2025, suggesting deal flow is concentrating in fewer high-value transactions. Notable deals included Eli Lilly's $55 million upfront collaboration with Nimbus Therapeutics, AstraZeneca's $1.2 billion upfront payment to CSPC Pharmaceutical for global rights to a dual GLP-1/GIP drug, and Pfizer's $495 million deal for Sciwind Biosciences' GLP-1 injection.openPR.comType 2 Diabetes Clinical Trial Pipeline Expands as 75+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AstraZeneca, Eli Lilly, Tonghua Dongbao, Sciwind BiosciencesDelveInsight published its 'Type 2 Diabetes - Pipeline Insight, 2026' report documenting 75+ companies developing 80+ pipeline drugs for Type 2 Diabetes treatment. On March 5, 2026, Eli Lilly initiated a Phase 3 study for retatrutide, and on March 3, 2026, AstraZeneca announced a Phase II study for AZD6234 in adults with obesity and Type 2 Diabetes. Additional therapies in earlier stages include Sciwind Biosciences' XW014 and Suzhou Alphamab's KN056, both GLP-1 receptor modulators currently in Phase I trials.openPR.comDiabetes Market: Rapid Increment Driven by Innovation by 2032 - DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNovaDelveInsight released a diabetes market report projecting significant growth during the 2019–2032 forecast period, driven by rising disease prevalence and an expanding pipeline of therapeutic candidates. Several regulatory and corporate developments shaped the diabetes landscape: the FDA approved Merilog (insulin-aspart-szjj) as the first rapid-acting biosimilar to NovoLog in February 2025, while also lifting a clinical hold on vTv Therapeutics' cadisegliatin program and issuing a safety alert on smartphone-dependent diabetes devices. In parallel, Vertex Pharmaceuticals halted its VX-264 cell therapy development, Novo Nordisk filed a Citizen Petition regarding liraglutide, and Eton Pharmaceuticals acquired U.S. rights to Amglidia for neonatal diabetes treatment.Investing.com5 ‘Healthy’ Dividends Paying Up to 14.1%This article reviews five high-yielding healthcare dividend stocks and funds, ranging from 6.0% to 14.1%, analyzing their fundamentals and investment viability amid sector turbulence. Pfizer faces a significant patent cliff with approximately $17 billion of annual revenue from drugs like Eliquis and Ibrance at risk through 2030, though its GLP-1 pipeline moves including a $7 billion acquisition of Metsera and collaborations with Chinese firms YaoPharma and Sciwind Biosciences represent potential offsets. Alexandria Real Estate Equities cut its dividend by 45% in December 2025, Healthpeak Properties announced a planned IPO spinoff of its senior housing portfolio as Janus Living, and two closed-end funds—BlackRock Health Sciences Trust (7.9% yield) and Abrdn Healthcare Investors (14.1% yield)—are presented as high-yield plays in the healthcare sector.